Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine Ophthalmic Solution in Allergic Conjunctivitis
NCT03479307Phase 3Completed
- Sponsor
- Faes Farma
- Start
- Apr 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bilastine in allergic conjunctivitis (AC), sponsored by Faes Farma. Started Apr 2018; status: completed.
02
Drugs
bilastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT03479307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03479307.